α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson's disease-like pathology: Molecular Therapy - Nucleic Acids

α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect

IJMS, Free Full-Text

Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease

α-Synuclein Aggregates Increase the Conductance of Substantia Nigra Dopamine Neurons, an Effect Partly Reversed by the KATP Channel Inhibitor Glibenclamide

Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Curcumin Interacts with α-Synuclein Condensates To Inhibit Amyloid Aggregation under Phase Separation

Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis - ScienceDirect

Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease: Trends in Endocrinology & Metabolism

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease

Current Progress in the Development of Probes for Targeting α-Synuclein Aggregates

Novel and rapid device opens new doors for Pa

Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms of Parkinson's Disease - Pharma Excipients

Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction